{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T05:28:51Z","timestamp":1782624531520,"version":"3.54.5"},"reference-count":58,"publisher":"e-Century Publishing Corporation","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/qwcq2468","type":"journal-article","created":{"date-parts":[[2025,6,29]],"date-time":"2025-06-29T23:56:06Z","timestamp":1751241366000},"page":"4101-4118","source":"Crossref","is-referenced-by-count":5,"title":["Chebulagic acid ameliorates DSS-induced colitis in mice by improving oxidative stress, inflammation and the gut microbiota"],"prefix":"10.62347","volume":"17","author":[{"given":"Song","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1016\/j.cgh.2022.06.030","article-title":"Global hospitalization trends for Crohn’s disease and ulcerative colitis in the 21st century: a systematic review with temporal analyses","volume":"21","author":"MJ","year":"2023","unstructured":"Buie MJ, Quan J, Windsor JW, Coward S, Hansen TM, King JA, Kotze PG, Gearry RB, Ng SC, Mak JWY, Abreu MT, Rubin DT, Bernstein CN, Banerjee R, Yamamoto-Furusho JK, Panaccione R, Seow CH, Ma C, Underwood FE, Ahuja V, Panaccione N, Shaheen AA, Holroyd-Leduc J, Kaplan GG; Global IBD Visualization of Epidemiology Studies in the 21st Century (GIVES-21) Research Group, Balderramo D, Chong VH, Juliao-Banos F, Dutta U, Simadibrata M, Kaibullayeva J, Sun Y, Hilmi I, Raja Ali RA, Paudel MS, Altuwaijri M, Hartono JL, Wei SC, Limsrivilai J, El Ouali S, Vergara BI, Dao VH, Kelly P, Hodges P, Miao Y and Li M. Global hospitalization trends for Crohn’s disease and ulcerative colitis in the 21st century: a systematic review with temporal analyses. Clin Gastroenterol Hepatol 2023; 21: 2211-2221.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.gtc.2020.07.005","article-title":"Epidemiology and pathogenesis of ulcerative colitis","volume":"49","author":"Du","year":"2020","unstructured":"Du L and Ha C. Epidemiology and pathogenesis of ulcerative colitis. Gastroenterol Clin North Am 2020; 49: 643-654.","journal-title":"Gastroenterol Clin North Am"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41575-022-00593-y","article-title":"Multiomics to elucidate inflammatory bowel disease risk factors and pathways","volume":"19","author":"Agrawal","year":"2022","unstructured":"Agrawal M, Allin KH, Petralia F, Colombel JF and Jess T. Multiomics to elucidate inflammatory bowel disease risk factors and pathways. Nat Rev Gastroenterol Hepatol 2022; 19: 399-409.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Shah SC and Itzkowitz SH. Colorectal cancer in inflammatory bowel disease: mechanisms and management. Gastroenterology 2022; 162: 715-730, e3.","DOI":"10.1053\/j.gastro.2021.10.035"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3349\/ymj.2021.62.2.99","article-title":"Incidence and prevalence of inflammatory bowel disease across Asia","volume":"62","author":"Park","year":"2021","unstructured":"Park J and Cheon JH. Incidence and prevalence of inflammatory bowel disease across Asia. Yonsei Med J 2021; 62: 99-108.","journal-title":"Yonsei Med J"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/17474124.2021.1840976","article-title":"Epidemiology, burden of disease, and unmet needs in the treatment of ulcerative colitis in Asia","volume":"15","author":"Wei","year":"2021","unstructured":"Wei SC, Sollano J, Hui YT, Yu W, Santos Estrella PV, Llamado LJQ and Koram N. Epidemiology, burden of disease, and unmet needs in the treatment of ulcerative colitis in Asia. Expert Rev Gastroenterol Hepatol 2021; 15: 275-289.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S2468-1253(21)00065-0","article-title":"Breaking the therapeutic ceiling in drug development in ulcerative colitis","volume":"6","author":"Alsoud","year":"2021","unstructured":"Alsoud D, Verstockt B, Fiocchi C and Vermeire S. Breaking the therapeutic ceiling in drug development in ulcerative colitis. Lancet Gastroenterol Hepatol 2021; 6: 589-595.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Krugliak Cleveland N, Torres J and Rubin DT. What does disease progression look like in ulcerative colitis, and how might it be prevented? Gastroenterology 2022; 162: 1396-1408.","DOI":"10.1053\/j.gastro.2022.01.023"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1080\/1744666X.2022.2069562","article-title":"Emerging therapies for ulcerative colitis","volume":"18","author":"Hanzel","year":"2022","unstructured":"Hanzel J, Hulshoff MS, Grootjans J and D’Haens G. Emerging therapies for ulcerative colitis. Expert Rev Clin Immunol 2022; 18: 513-524.","journal-title":"Expert Rev Clin Immunol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/25785826.2020.1792040","article-title":"Fecal microbiota transplantation for ulcerative colitis","volume":"44","author":"Matsuoka","year":"2021","unstructured":"Matsuoka K. Fecal microbiota transplantation for ulcerative colitis. Immunol Med 2021; 44: 30-34.","journal-title":"Immunol Med"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Hassan Bulbul MR, Uddin Chowdhury MN, Naima TA, Sami SA, Imtiaj MS, Huda N and Uddin MG. A comprehensive review on the diverse pharmacological perspectives of Terminalia chebula Retz. Heliyon 2022; 8: e10220.","DOI":"10.1016\/j.heliyon.2022.e10220"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1002\/ptr.6702","article-title":": a review on traditional uses, bioactive chemical constituents and pharmacological activities","volume":"34","author":"Nigam","year":"2020","unstructured":"Nigam M, Mishra AP, Adhikari-Devkota A, Dirar AI, Hassan MM, Adhikari A, Belwal T and Devkota HP. Fruits of Terminalia chebula Retz.: a review on traditional uses, bioactive chemical constituents and pharmacological activities. Phytother Res 2020; 34: 2518-2533.","journal-title":"Phytother Res"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"129833","DOI":"10.1016\/j.foodchem.2021.129833","article-title":"Hydrolysable tannins in Terminalia ferdinandiana Exell fruit powder and comparison of their functional properties from different solvent extracts","volume":"358","author":"Bobasa","year":"2021","unstructured":"Bobasa EM, Phan ADT, Netzel ME, Cozzolino D and Sultanbawa Y. Hydrolysable tannins in Terminalia ferdinandiana Exell fruit powder and comparison of their functional properties from different solvent extracts. Food Chem 2021; 358: 129833.","journal-title":"Food Chem"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1143427","DOI":"10.3389\/fphar.2023.1143427","article-title":"Chebulagic acid suppresses gastric cancer by inhibiting the AURKA\/beta-catenin\/Wnt pathway","volume":"14","author":"Zhao","year":"2023","unstructured":"Zhao J, Shi Y, Ma Y, Pan L, Wang Y, Yuan L, Dong J and Ying J. Chebulagic acid suppresses gastric cancer by inhibiting the AURKA\/beta-catenin\/Wnt pathway. Front Pharmacol 2023; 14: 1143427.","journal-title":"Front Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"105075","DOI":"10.1016\/j.antiviral.2021.105075","article-title":"Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CL(pro)","volume":"190","author":"Du","year":"2021","unstructured":"Du R, Cooper L, Chen Z, Lee H, Rong L and Cui Q. Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CL(pro). Antiviral Res 2021; 190: 105075.","journal-title":"Antiviral Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"9650","DOI":"10.1021\/acsnano.7b03239","article-title":"Bioengineering bacterially derived immunomodulants: a therapeutic approach to inflammatory bowel disease","volume":"11","author":"Herrera Estrada","year":"2017","unstructured":"Herrera Estrada L, Wu H, Ling K, Zhang G, Sumagin R, Parkos CA, Jones RM, Champion JA and Neish AS. Bioengineering bacterially derived immunomodulants: a therapeutic approach to inflammatory bowel disease. ACS Nano 2017; 11: 9650-9662.","journal-title":"ACS Nano"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.freeradbiomed.2017.11.005","article-title":"SIRT6 protects against hepatic ischemia\/reperfusion injury by inhibiting apoptosis and autophagy related cell death","volume":"115","author":"Zhang","year":"2018","unstructured":"Zhang S, Jiang S, Wang H, Di W, Deng C, Jin Z, Yi W, Xiao X, Nie Y and Yang Y. SIRT6 protects against hepatic ischemia\/reperfusion injury by inhibiting apoptosis and autophagy related cell death. Free Radic Biol Med 2018; 115: 18-30.","journal-title":"Free Radic Biol Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"121312","DOI":"10.1016\/j.lfs.2022.121312","article-title":"Deferasirox alleviates DSS-induced ulcerative colitis in mice by inhibiting ferroptosis and improving intestinal microbiota","volume":"314","author":"Wu","year":"2023","unstructured":"Wu Y, Ran L, Yang Y, Gao X, Peng M, Liu S, Sun L, Wan J, Wang Y, Yang K, Yin M and Chunyu W. Deferasirox alleviates DSS-induced ulcerative colitis in mice by inhibiting ferroptosis and improving intestinal microbiota. Life Sci 2023; 314: 121312.","journal-title":"Life Sci"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"11411","DOI":"10.3390\/ijms222111411","article-title":"Triggers for the Nrf2\/ARE signaling pathway and its nutritional regulation: potential therapeutic applications of ulcerative colitis","volume":"22","author":"Liu","year":"2021","unstructured":"Liu H, Johnston LJ, Wang F and Ma X. Triggers for the Nrf2\/ARE signaling pathway and its nutritional regulation: potential therapeutic applications of ulcerative colitis. Int J Mol Sci 2021; 22: 11411.","journal-title":"Int J Mol Sci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1093\/ibd\/izz149","article-title":"Inflammation and inflammatory cytokine contribute to the initiation and development of ulcerative colitis and its associated cancer","volume":"25","author":"Yao","year":"2019","unstructured":"Yao D, Dong M, Dai C and Wu S. Inflammation and inflammatory cytokine contribute to the initiation and development of ulcerative colitis and its associated cancer. Inflamm Bowel Dis 2019; 25: 1595-1602.","journal-title":"Inflamm Bowel Dis"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"761981","DOI":"10.3389\/fimmu.2021.761981","article-title":"Interaction between commensal bacteria, immune response and the intestinal barrier in inflammatory bowel disease","volume":"12","author":"Chen","year":"2021","unstructured":"Chen Y, Cui W, Li X and Yang H. Interaction between commensal bacteria, immune response and the intestinal barrier in inflammatory bowel disease. Front Immunol 2021; 12: 761981.","journal-title":"Front Immunol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jcmgh.2017.03.007","article-title":"Mend your fences: the epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease","volume":"4","author":"Martini","year":"2017","unstructured":"Martini E, Krug SM, Siegmund B, Neurath MF and Becker C. Mend your fences: the epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease. Cell Mol Gastroenterol Hepatol 2017; 4: 33-46.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"806148","DOI":"10.3389\/fphar.2022.806148","article-title":"Natural products modulate cell apoptosis: a promising way for the treatment of ulcerative colitis","volume":"13","author":"Liu","year":"2022","unstructured":"Liu C, Zeng Y, Wen Y, Huang X and Liu Y. Natural products modulate cell apoptosis: a promising way for the treatment of ulcerative colitis. Front Pharmacol 2022; 13: 806148.","journal-title":"Front Pharmacol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1080\/15548627.2019.1635384","article-title":"New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD","volume":"16","author":"Larabi","year":"2020","unstructured":"Larabi A, Barnich N and Nguyen HTT. New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD. Autophagy 2020; 16: 38-51.","journal-title":"Autophagy"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41572-020-0205-x","article-title":"Ulcerative colitis","volume":"6","author":"Kobayashi","year":"2020","unstructured":"Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, Bernstein CN, Danese S, Peyrin-Biroulet L and Hibi T. Ulcerative colitis. Nat Rev Dis Primers 2020; 6: 74.","journal-title":"Nat Rev Dis Primers"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1142\/S0192415X22500756","article-title":"Chinese medicine in the treatment of ulcerative colitis: the mechanisms of signaling pathway regulations","volume":"50","author":"Zheng","year":"2022","unstructured":"Zheng S, Xue T, Wang B, Guo H and Liu Q. Chinese medicine in the treatment of ulcerative colitis: the mechanisms of signaling pathway regulations. Am J Chin Med 2022; 50: 1781-1798.","journal-title":"Am J Chin Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"115084","DOI":"10.1016\/j.jep.2022.115084","article-title":"Potential activity of traditional Chinese medicine against ulcerative colitis: a review","volume":"289","author":"Liu","year":"2022","unstructured":"Liu Y, Li BG, Su YH, Zhao RX, Song P, Li H, Cui XH, Gao HM, Zhai RX, Fu XJ and Ren X. Potential activity of traditional Chinese medicine against ulcerative colitis: a review. J Ethnopharmacol 2022; 289: 115084.","journal-title":"J Ethnopharmacol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/S2221-1691(13)60059-3","article-title":"(Combretaceae) in clinical research","volume":"3","author":"Bag","year":"2013","unstructured":"Bag A, Bhattacharyya SK and Chattopadhyay RR. The development of Terminalia chebula Retz. (Combretaceae) in clinical research. Asian Pac J Trop Biomed 2013; 3: 244-252.","journal-title":"Asian Pac J Trop Biomed"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3390\/antibiotics8040194","article-title":"Antibacterial activities, phytochemical screening and metal analysis of medicinal plants: traditional recipes used against diarrhea","volume":"8","author":"Mahmood","year":"2019","unstructured":"Mahmood N, Nazir R, Khan M, Khaliq A, Adnan M, Ullah M and Yang H. Antibacterial activities, phytochemical screening and metal analysis of medicinal plants: traditional recipes used against diarrhea. Antibiotics (Basel) 2019; 8: 194.","journal-title":"Antibiotics (Basel)"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"867692","DOI":"10.3389\/fnut.2022.867692","article-title":"Integrated analysis reveals the targets and mechanisms in immunosuppressive effect of mesalazine on ulcerative colitis","volume":"9","author":"Li","year":"2022","unstructured":"Li R, Huang X, Yang L, Liang X, Huang W, Lai KP and Zhou L. Integrated analysis reveals the targets and mechanisms in immunosuppressive effect of mesalazine on ulcerative colitis. Front Nutr 2022; 9: 867692.","journal-title":"Front Nutr"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Li L, Peng P, Ding N, Jia W, Huang C and Tang Y. Oxidative stress, inflammation, gut dysbiosis: what can polyphenols do in inflammatory bowel disease? Antioxidants (Basel) 2023; 12: 967.","DOI":"10.3390\/antiox12040967"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/s41423-022-00902-0","article-title":"Redox regulation of the immune response","volume":"19","author":"Morris","year":"2022","unstructured":"Morris G, Gevezova M, Sarafian V and Maes M. Redox regulation of the immune response. Cell Mol Immunol 2022; 19: 1079-1101.","journal-title":"Cell Mol Immunol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"114304","DOI":"10.1016\/j.jep.2021.114304","article-title":"ameliorates ulcerative colitis via inhibiting NF-kappaB and MAPK activation and mediating intestinal barrier integrity","volume":"278","author":"Deng","year":"2021","unstructured":"Deng X, Wang Y, Tian L, Yang M, He S, Liu Y, Khan A, Li Y, Cao J and Cheng G. Anneslea fragrans Wall. ameliorates ulcerative colitis via inhibiting NF-kappaB and MAPK activation and mediating intestinal barrier integrity. J Ethnopharmacol 2021; 278: 114304.","journal-title":"J Ethnopharmacol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.2174\/1389201021666191216122555","article-title":"Targeting mitogen-activated protein kinases by natural products: a novel therapeutic approach for inflammatory bowel diseases","volume":"21","author":"Zobeiri","year":"2020","unstructured":"Zobeiri M, Momtaz S, Parvizi F, Tewari D, Farzaei MH and Nabavi SM. Targeting mitogen-activated protein kinases by natural products: a novel therapeutic approach for inflammatory bowel diseases. Curr Pharm Biotechnol 2020; 21: 1342-1353.","journal-title":"Curr Pharm Biotechnol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.intimp.2018.02.012","article-title":"Andrographolide derivative CX-10 ameliorates dextran sulphate sodium-induced ulcerative colitis in mice: involvement of NF-kappaB and MAPK signalling pathways","volume":"57","author":"Gao","year":"2018","unstructured":"Gao Z, Yu C, Liang H, Wang X, Liu Y, Li X, Ji K, Xu H, Yang M, Liu K, Qi D and Fan H. Andrographolide derivative CX-10 ameliorates dextran sulphate sodium-induced ulcerative colitis in mice: involvement of NF-kappaB and MAPK signalling pathways. Int Immunopharmacol 2018; 57: 82-90.","journal-title":"Int Immunopharmacol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"114739","DOI":"10.1016\/j.jep.2021.114739","article-title":"Ginseng root extract attenuates inflammation by inhibiting the MAPK\/NF-kappaB signaling pathway and activating autophagy and p62-Nrf2-Keap1 signaling in vitro and in vivo","volume":"283","author":"Yang","year":"2022","unstructured":"Yang S, Li F, Lu S, Ren L, Bian S, Liu M, Zhao D, Wang S and Wang J. Ginseng root extract attenuates inflammation by inhibiting the MAPK\/NF-kappaB signaling pathway and activating autophagy and p62-Nrf2-Keap1 signaling in vitro and in vivo. J Ethnopharmacol 2022; 283: 114739.","journal-title":"J Ethnopharmacol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/jpp\/rgab178","article-title":"7 cells","volume":"74","author":"Ekambaram","year":"2022","unstructured":"Ekambaram SP, Aruldhas J, Srinivasan A and Erusappan T. Modulation of NF-kappaB and MAPK signalling pathways by hydrolysable tannin fraction from Terminalia chebula fruits contributes to its anti-inflammatory action in RAW 264.7 cells. J Pharm Pharmacol 2022; 74: 718-729.","journal-title":"J Pharm Pharmacol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.vph.2018.04.005","article-title":"Chebulagic acid Chebulinic acid and Gallic acid, the active principles of Triphala, inhibit TNFalpha induced pro-angiogenic and pro-inflammatory activities in retinal capillary endothelial cells by inhibiting p38, ERK and NFkB phosphorylation","volume":"108","author":"Shanmuganathan","year":"2018","unstructured":"Shanmuganathan S and Angayarkanni N. Chebulagic acid Chebulinic acid and Gallic acid, the active principles of Triphala, inhibit TNFalpha induced pro-angiogenic and pro-inflammatory activities in retinal capillary endothelial cells by inhibiting p38, ERK and NFkB phosphorylation. Vascul Pharmacol 2018; 108: 23-35.","journal-title":"Vascul Pharmacol"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Arda-Pirincci P and Aykol-Celik G. Galectin-1 reduces the severity of dextran sulfate sodium (DSS)-induced ulcerative colitis by suppressing inflammatory and oxidative stress response. Bosn J Basic Med Sci 2020; 20: 319-328.","DOI":"10.17305\/bjbms.2019.4539"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.freeradbiomed.2019.12.012","article-title":"Rutaecarpine inhibits KEAP1-NRF2 interaction to activate NRF2 and ameliorate dextran sulfate sodium-induced colitis","volume":"148","author":"Zhang","year":"2020","unstructured":"Zhang Y, Yan T, Sun D, Xie C, Wang T, Liu X, Wang J, Wang Q, Luo Y, Wang P, Yagai T, Krausz KW, Yang X and Gonzalez FJ. Rutaecarpine inhibits KEAP1-NRF2 interaction to activate NRF2 and ameliorate dextran sulfate sodium-induced colitis. Free Radic Biol Med 2020; 148: 33-41.","journal-title":"Free Radic Biol Med"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"817596","DOI":"10.3389\/fphar.2022.817596","article-title":"Dehydrocostus lactone suppresses dextran sulfate sodium-induced colitis by targeting the IKKalpha\/beta-NF-kappaB and Keap1-Nrf2 signalling pathways","volume":"13","author":"Yuan","year":"2022","unstructured":"Yuan Y, Hu Q, Liu L, Xie F, Yang L, Li Y, Zhang C, Chen H, Tang J and Shen X. Dehydrocostus lactone suppresses dextran sulfate sodium-induced colitis by targeting the IKKalpha\/beta-NF-kappaB and Keap1-Nrf2 signalling pathways. Front Pharmacol 2022; 13: 817596.","journal-title":"Front Pharmacol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41419-020-2299-1","article-title":"Ferroptosis involves in intestinal epithelial cell death in ulcerative colitis","volume":"11","author":"Xu","year":"2020","unstructured":"Xu M, Tao J, Yang Y, Tan S, Liu H, Jiang J, Zheng F and Wu B. Ferroptosis involves in intestinal epithelial cell death in ulcerative colitis. Cell Death Dis 2020; 11: 86.","journal-title":"Cell Death Dis"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.freeradbiomed.2022.06.242","article-title":"STAT3-mediated ferroptosis is involved in ulcerative colitis","volume":"188","author":"Huang","year":"2022","unstructured":"Huang F, Zhang S, Li X, Huang Y, He S and Luo L. STAT3-mediated ferroptosis is involved in ulcerative colitis. Free Radic Biol Med 2022; 188: 375-385.","journal-title":"Free Radic Biol Med"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.imlet.2020.06.005","article-title":"Ferroptosis mediated DSS-induced ulcerative colitis associated with Nrf2\/HO-1 signaling pathway","volume":"225","author":"Chen","year":"2020","unstructured":"Chen Y, Zhang P, Chen W and Chen G. Ferroptosis mediated DSS-induced ulcerative colitis associated with Nrf2\/HO-1 signaling pathway. Immunol Lett 2020; 225: 9-15.","journal-title":"Immunol Lett"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"4300","DOI":"10.3390\/molecules26144300","article-title":"Ferroptosis-inhibitory difference between chebulagic acid and chebulinic acid indicates beneficial role of HHDP","volume":"26","author":"Yang","year":"2021","unstructured":"Yang L, Liu Y, Zhang W, Hua Y, Chen B, Wu Q, Chen D, Liu S and Li X. Ferroptosis-inhibitory difference between chebulagic acid and chebulinic acid indicates beneficial role of HHDP. Molecules 2021; 26: 4300.","journal-title":"Molecules"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0126-x","article-title":"Mechanisms regulating intestinal barrier integrity and its pathological implications","volume":"50","author":"Chelakkot","year":"2018","unstructured":"Chelakkot C, Ghim J and Ryu SH. Mechanisms regulating intestinal barrier integrity and its pathological implications. Exp Mol Med 2018; 50: 1-9.","journal-title":"Exp Mol Med"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41575-020-00399-w","article-title":"The intestinal barrier, an arbitrator turned provocateur in IBD","volume":"18","author":"Mehandru","year":"2021","unstructured":"Mehandru S and Colombel JF. The intestinal barrier, an arbitrator turned provocateur in IBD. Nat Rev Gastroenterol Hepatol 2021; 18: 83-84.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1093\/ibd\/izab277","article-title":"Excessive apoptosis in ulcerative colitis: crosstalk between apoptosis, ROS, ER stress, and intestinal homeostasis","volume":"28","author":"Wan","year":"2022","unstructured":"Wan Y, Yang L, Jiang S, Qian D and Duan J. Excessive apoptosis in ulcerative colitis: crosstalk between apoptosis, ROS, ER stress, and intestinal homeostasis. Inflamm Bowel Dis 2022; 28: 639-648.","journal-title":"Inflamm Bowel Dis"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.molmed.2020.06.006","article-title":"Oxidative stress and redox-modulating therapeutics in inflammatory bowel disease","volume":"26","author":"Bourgonje","year":"2020","unstructured":"Bourgonje AR, Feelisch M, Faber KN, Pasch A, Dijkstra G and van Goor H. Oxidative stress and redox-modulating therapeutics in inflammatory bowel disease. Trends Mol Med 2020; 26: 1034-1046.","journal-title":"Trends Mol Med"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1136\/gutjnl-2015-310096","article-title":"Raf kinase inhibitor protein mediates intestinal epithelial cell apoptosis and promotes IBDs in humans and mice","volume":"66","author":"Lin","year":"2017","unstructured":"Lin W, Ma C, Su F, Jiang Y, Lai R, Zhang T, Sun K, Fan L, Cai Z, Li Z, Huang H, Li J and Wang X. Raf kinase inhibitor protein mediates intestinal epithelial cell apoptosis and promotes IBDs in humans and mice. Gut 2017; 66: 597-610.","journal-title":"Gut"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"928116","DOI":"10.3389\/fbinf.2022.928116","article-title":"Application of network pharmacology in the study of mechanism of Chinese medicine in the treatment of ulcerative colitis: a review","volume":"2","author":"Zheng","year":"2022","unstructured":"Zheng S, Xue T, Wang B, Guo H and Liu Q. Application of network pharmacology in the study of mechanism of Chinese medicine in the treatment of ulcerative colitis: a review. Front Bioinform 2022; 2: 928116.","journal-title":"Front Bioinform"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"603476","DOI":"10.3389\/fphar.2020.603476","article-title":"Efficacy and safety of sophora flavescens (Kushen) based traditional chinese medicine in the treatment of ulcerative colitis: clinical evidence and potential mechanisms","volume":"11","author":"Chen","year":"2020","unstructured":"Chen M, Ding Y and Tong Z. Efficacy and safety of sophora flavescens (Kushen) based traditional chinese medicine in the treatment of ulcerative colitis: clinical evidence and potential mechanisms. Front Pharmacol 2020; 11: 603476.","journal-title":"Front Pharmacol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41575-019-0121-2","article-title":"The gut mycobiota: insights into analysis, environmental interactions and role in gastrointestinal diseases","volume":"16","author":"Richard","year":"2019","unstructured":"Richard ML and Sokol H. The gut mycobiota: insights into analysis, environmental interactions and role in gastrointestinal diseases. Nat Rev Gastroenterol Hepatol 2019; 16: 331-345.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"8075344","DOI":"10.1155\/2022\/8075344","article-title":"Traditional chinese medicine alleviates ulcerative colitis via modulating gut microbiota","volume":"2022","author":"Feng","year":"2022","unstructured":"Feng W, Zhu L and Shen H. Traditional chinese medicine alleviates ulcerative colitis via modulating gut microbiota. Evid Based Complement Alternat Med 2022; 2022: 8075344.","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"679897","DOI":"10.3389\/fimmu.2021.679897","article-title":"Kaempferol alleviates murine experimental colitis by restoring gut microbiota and inhibiting the LPS-TLR4-NF-kappaB axis","volume":"12","author":"Qu","year":"2021","unstructured":"Qu Y, Li X, Xu F, Zhao S, Wu X, Wang Y and Xie J. Kaempferol alleviates murine experimental colitis by restoring gut microbiota and inhibiting the LPS-TLR4-NF-kappaB axis. Front Immunol 2021; 12: 679897.","journal-title":"Front Immunol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/1348-0421.12749","article-title":"Effect of cinnamon essential oil on gut microbiota in the mouse model of dextran sodium sulfate-induced colitis","volume":"64","author":"AL","year":"2020","unstructured":"Li AL, Ni WW, Zhang QM, Li Y, Zhang X, Wu HY, Du P, Hou JC and Zhang Y. Effect of cinnamon essential oil on gut microbiota in the mouse model of dextran sodium sulfate-induced colitis. Microbiol Immunol 2020; 64: 23-32.","journal-title":"Microbiol Immunol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1010853","DOI":"10.3389\/fcimb.2022.1010853","article-title":"The oral-gut axis: salivary and fecal microbiome dysbiosis in patients with inflammatory bowel disease","volume":"12","author":"Abdelbary","year":"2022","unstructured":"Abdelbary MMH, Hatting M, Bott A, Dahlhausen A, Keller D, Trautwein C and Conrads G. The oral-gut axis: salivary and fecal microbiome dysbiosis in patients with inflammatory bowel disease. Front Cell Infect Microbiol 2022; 12: 1010853.","journal-title":"Front Cell Infect Microbiol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.3390\/nu14051069","article-title":"Taxifolin alleviates DSS-induced ulcerative colitis by acting on gut microbiome to produce butyric acid","volume":"14","author":"Li","year":"2022","unstructured":"Li W, Zhang L, Xu Q, Yang W, Zhao J, Ren Y, Yu Z and Ma L. Taxifolin alleviates DSS-induced ulcerative colitis by acting on gut microbiome to produce butyric acid. Nutrients 2022; 14: 1069.","journal-title":"Nutrients"}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/6\/ajtr0161601.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:57:16Z","timestamp":1766023036000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/17\/6\/ajtr0161601.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":58,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/qwcq2468","relation":{},"ISSN":["1943-8141"],"issn-type":[{"value":"1943-8141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}